EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseVergleichsstudieÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials

Najwaa Kirmani, Nathalia De León-Fernández, Juan David Rodriguez-Parra, Laura Ghanem, Bezalel Hakkeem, Clara Briceño-Morales, Ximena Briceño-Morales

Cancer Treatment Reviews · 2026

DOI: 10.1016/j.ctrv.2026.103093 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Treatment Reviews, 2026. Verfasst von Najwaa Kirmani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dow Medical College, Karachi, Pakistan. Hauptthemen laut MEDLINE: Breast Neoplasms, Selective Estrogen Receptor Modulators. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsSelective Estrogen Receptor ModulatorsHumansFemaleRandomized Controlled Trials as TopicErb-b2 Receptor Tyrosine KinasesAdministration, OralReceptors, EstrogenEstrogen Receptor alphaFulvestrant

Stichwörter der Autor:innen

Breast NeoplasmESR1 protein, humanEndocrine ResistanceEstrogen AntagonistsSelective Estrogen Receptor DegradersSystematic Review

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanSelective Estrogen Receptor ModulatorsReceptors, EstrogenEstrogen Receptor alphaFulvestrant

Autor:innen und Institutionen

  • Dow Medical College, Karachi, Pakistan.
  • Universidad de los Andes, Bogotá, Colombia.
  • Pontificia Universidad Javeriana, Bogotá, Colombia.
  • Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
  • Government Medical College Kozhikode, Kerala, India.
  • Grupo de Investigación en Ciencias Quirúrgicas, Departamento de Ciencias Clínicas, Universidad Tecnológica de Pereira, Pereira, Colombia; Institución Universitaria Visión de las Américas, Pereira, Colombia. Electronic a…

Zitieren

APA

Kirmani, N., De León-Fernández, N., Rodriguez-Parra, J. D., Ghanem, L., Hakkeem, B., Briceño-Morales, C., & Briceño-Morales, X. (2026). Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials. Cancer Treatment Reviews. https://doi.org/10.1016/j.ctrv.2026.103093

Vancouver

Kirmani N, De León-Fernández N, Rodriguez-Parra JD, Ghanem L, Hakkeem B, Briceño-Morales C, et al. Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials. Cancer Treatment Reviews. 2026. doi:10.1016/j.ctrv.2026.103093

BibTeX
@article{Kirmani2026,
  author = {Kirmani, Najwaa and De León-Fernández, Nathalia and Rodriguez-Parra, Juan David and Ghanem, Laura and Hakkeem, Bezalel and Briceño-Morales, Clara and Briceño-Morales, Ximena},
  title = {Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  doi = {10.1016/j.ctrv.2026.103093}
}
Kostenlos starten →